Imunon raises $7.0M in registered direct offering of common stock and warrants

Imunon, Inc.

Gross proceeds ~$7.0M from 1,939,114 shares/pre-funded warrants plus warrants at $3.61/unit.
Warrants exercisable at $3.482/share for 5 years; pre-funded warrants at $0.0001, no expiration.
Offering priced at-the-market under Nasdaq rules; expected to close December 31, 2025.
Net proceeds for general corporate purposes including R&D, capex, and working capital.
Maxim Group LLC is lead placement agent; Brookline Capital Markets is co-placement agent.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Imunon, Inc. entered into Securities Purchase Agreement with a single healthcare-focused institutional investor valued at combined offering price of $3.61 per Share and Warrant (effective 2025-12-29).

Action: entry
Agreement: equity purchase
Counterparty: a single healthcare-focused institutional investor
Value: combined offering price of $3.61 per Share and Warrant
Effective: 2025-12-29

Exact text from the filing

On December 29, 2025, Imunon, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with a single healthcare-focused institutional investor (the “Purchaser”) for a registered direct offering

View on SEC.gov

290 material agreements filed in the last 30 days. Browse all material agreements →

Imunon, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-25-029711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.